Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering
06. Dezember 2024 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging...
Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering
25. November 2024 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging...
Eyenovia Provides Update on Restructuring Efforts
22. November 2024 07:00 ET
|
Eyenovia, Inc.
Avenue Capital agrees to Company’s deferral of principal and interest payments on its outstanding debt until the end of February 2025 Eyenovia continues to evaluate a broad range of strategic...
Eyenovia Provides Update on Phase 3 CHAPERONE Study
15. November 2024 07:00 ET
|
Eyenovia, Inc.
A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue study, review full data set, and...
Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update
12. November 2024 16:05 ET
|
Eyenovia, Inc.
Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for interim analysis this quarter Commenced the manufacture of registration batches of...
Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th
07. November 2024 07:00 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet...
Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®
23. Oktober 2024 07:00 ET
|
Eyenovia, Inc.
Publication in the Journal of Ocular Pharmacology and Therapeutics highlights the ability of the Optejet to achieve a therapeutic dose of medication with far less exposure to harmful preservatives ...
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo
16. Oktober 2024 07:00 ET
|
Eyenovia, Inc.
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced a presentation at the American Academy of Ophthalmology (AAO) 2024 Expo,...
Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device
01. Oktober 2024 07:00 ET
|
Eyenovia, Inc.
NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced that the Company has commenced manufacturing of registration batches of...
Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering
27. September 2024 08:30 ET
|
Eyenovia, Inc.
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company with two FDA-approved products and a late-stage asset in...